References
Booysen, P., Wilkinson, K. A., Sheerin, D., & Waters, R. (2023). Immune interaction between SARS?CoV?2 and Mycobacterium tuberculosis. Frontiers in Immunology, 14, 1254206. Bryan, A., Pepper, G., Wener, M. H., Fink, S. L., Morishima, C., Chaudhary, A.,Jerome, K. R. (2020). Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. Journal of Clinical Microbiology, 58(8), e00941-20. Cheesbrough, M. (2010). District Laboratory practice in tropical countries (2nd ed.). Cambridge University Press. Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H. & Ning, Q. (2020). Clinical and immunological features of severe and moderate SARS-CoV-2 infection. Journal of Clinical Investigation, 130(5), 2620–2629. Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., ... Chen, Y. (2020). Reduction and Functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Frontiers in Immunology, 11, 827. Flynn, J. L., & Chan, J. (2001). Immunology of tuberculosis. Annual Review of Immunology, 19, 93–129. IBM Corp. (2011). IBM SPSS Statistics for Windows (Version 20.0). IBM Corp. Kolawole, O. M., Adu, F. D., Olasode, O. A., Omisakin, C. T., & Oladipo, E. K. (2022). Seroprevalence of SARS-CoV-2 antibodies in Nigeria: Evidence of widespread community transmission. BMC Infectious Diseases, 22, 734. Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., ... Huang, A. L. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine, 26(6), 845–848. Motta, I., Centis, R., D’Ambrosio, L., García-García, J. M., Goletti, D., Gualano, G., ...Migliori, G. B. (2020). Tuberculosis and SARS-CoV-2: Syndemic interactions and clinical implications. Pulmonology, 26(4), 233–240. Putri, A. R., Wahyunitisari, M. R., Wulandari, L., &Rachman, B. E. (2024). Understanding the tuberculosis and COVID?19 co?infection: A comprehensive review of immunopathological dynamics and pandemic’s disruption in TB services. World Journal of Advanced Research and Reviews, 24(03), 1204–1211. Rajamanickam, A., Pavan Kumar, N., Chandrasekaran, P., Nancy, A., Nandhini, S., Kushiyasri, K., Munisankar, S., Shrinivasa, B. M., Renji, R. M., Ambu, T. C., Venkataramani, V., & Babu, S. (2021). Latent tuberculosis co?infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS?CoV?2 infection. Journal of Infection, 83(3), 339–346. Setia, M. S. (2016). Methodology series module 3: Cross-sectional studies. Indian Journal of Dermatology, 61(3), 261–264. Sette, A., &Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 184(4), 861–880. Tadolini, M., Codecasa, L. R., García-García, J. M., Blanc, F. X., Borisov, S., Alffenaar, J. W.,...Migliori, G. B. (2020). Active tuberculosis, sequelae and COVID-19 co-infection: A multicentre cohort study. European Respiratory Journal, 56(1), 2001398. Tamuzi, J. L., Ayele, B. T., Shumba, C. S., Adetokunboh, O. O., Uwimana-Nicol, J., Haile, Z. T., &Nyasulu, P. S. (2020). Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. BMC Infectious Diseases, 20, 744. Tewari, S., &Yadav, R. (2022). COVID?19 and tuberculosis reactivation: A systematic review assessing most common risk factors. International Journal of Basic & Clinical Pharmacology.184(4), 861–880. Visca, D., Ong, C. W. M., Tiberi, S., Centis, R., D’Ambrosio, L., Chen, B., ...Migliori, G. B. (2021). Tuberculosis and COVID-19 interaction: A review of biological, clinical and Public Health effects. Pulmonology, 27(2), 151–165. Wang, Q., Cao, Y., Liu, X., Fu, Y., Zhang, J., Zhang, Y., Zhang, L., Wei, X., & Yang, L. (2024). Systematic review and meta?analysis of tuberculosis and COVID?19 co?infection: Prevalence, fatality, and treatment considerations. PLOS Neglected Tropical Diseases, 18(5), Article e0012136. Wang, Q., Guo, S., Wei, X., Dong, Q., Xu, N., & Li, H. (2022). Global prevalence, treatment and outcome of tuberculosis and COVID-19 coinfection: A systematic review and meta- analysis. BMJ Open, 12(6), e059396 World Health Organization. (2023). Global tuberculosis report 2023: TB situation and response (p. Factsheet). https://cdn.who.int/media/docs/default?source/hq?tuberculosis/global?tb?report?2023?facts heet.pdf. World Health Organization. (2010). WHO guidelines on drawing blood: Best practices in phlebotomy. WHO Press. World Health Organization. (2014). Xpert MTB/RIF implementation manual: Technical and operational “how-to”. WHO Press. World Health Organization. (2021). WHO consolidated guidelines on tuberculosis: Module 2 – Screening and diagnosis. WHO Press. World Health Organization. (2023). Global tuberculosis report 2023. World Health Organization. Zhang, R., Conejero, L., Martín, C., López, Y., & Hidalgo, J. (2023). Characterization of the immune impairment of patients with tuberculosis and COVID?19 coinfection. Journal of Infection and Public Health.
